Skip to main content

Day: November 26, 2023

Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Nov. 26, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has filed for orphan drug designation (ODD) and rare pediatric disease designation (RPDD) with the United States Food and Drug Administration (FDA) for its allogeneic cell therapy Revascor® (rexlemestrocel-L) in the treatment of the congenital heart disease hypoplastic left heart syndrome (HLHS). The filings were based on results from a blinded, randomized, controlled prospective trial of REVASCOR conducted at a single center in the US in 19 children with HLHS and accepted for publication in an upcoming issue of the peer reviewed The Journal of Thoracic and Cardiovascular Surgery Open (JTCVS Open).1 HLHS is a severe congenital heart disease in which...

Continue reading

Empowering Nutrition: Unveiling the Dynamics of Food Fortifying Agents Market

Written by Customer Service on . Posted in Mergers And Acquisitions.

Chicago, Nov. 26, 2023 (GLOBE NEWSWIRE) — The global food fortifying agents market refers to the market for substances added to food to enhance its nutritional content. Food fortifying agents are used to address nutrient deficiencies and improve the overall nutritional profile of food products. These agents may include vitamins, minerals, and other nutrients that may be lacking in the diet or may be lost during food processing. The global market for food fortifying agents has been growing as consumers become more conscious of their health and nutrition. Fortified foods offer a convenient way to ensure that individuals receive essential nutrients, especially when certain nutrients are not naturally present in sufficient quantities in the diet. According to MarketsandMarkets, the global food fortifying agents market size is projected...

Continue reading

BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November 2023 relating to the rights offering and publishes updated Basic Information Document

Written by Customer Service on . Posted in Public Companies.

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 26th of November 2023 at 6.40 p.m. EET BBS-Bioactive Bone Substitutes Plc has received new subscription undertakings and supplements the Investor Memorandum dated 24th of November 2023 relating to the rights offering and publishes updated Basic Information Document NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL. BBS-Bioactive Bone Substitutes Plc (“BBS” or the “Company”) has announced on 20th of November 2023 that based on authorization granted by the Extraordinary General Meeting on 23rd of October 2023, the Board of Directors of the Company has decided to arrange...

Continue reading

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

Written by Customer Service on . Posted in Public Companies.

–  Oral presentation on MCLA-129 in combination with osimertinib as first line therapy, and in previously treated, NSCLC on Sunday, December 3 at 9:40 a.m. SGT  –  Poster presentation on MCLA-129 in previously treated HNSCC on Saturday, December 2 at 17:50 p.m. SGT –  Investor call on Monday, November 27, 2023 8:00 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 26, 2023 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of two abstracts regarding MCLA-129 on the European Society for Medical Oncology (ESMO) Asia Congress website. The abstracts highlight updated interim clinical data from expansion cohorts in non-small...

Continue reading

Philips showcases world’s first mobile MRI system with helium-free operations at #RSNA23

Written by Customer Service on . Posted in Public Companies.

Philips Mobile MRI system expanding access to careInterior view of Philips Mobile MRPhilips MR Mobile connected to Philips’ Radiology Operations Command Center (ROCC)November 26, 2023 BlueSeal MR Mobile’s unique magnet technology advances patient outcomes and access to care with high quality diagnostic imaging and enhanced workflows Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today showcases the world’s first mobile MRI system with helium-free operations at #RSNA23. BlueSeal MR Mobile [1], the industry’s first and only 1.5T fully sealed magnet, delivers patient-centric MRI services where and whenever needed. Unlike other mobile MRI scanners, the BlueSeal MR Mobile is more agile and lightweight so it can be located in more convenient...

Continue reading

Updated Notice Regarding Approval of Supplement to Base Prospectus and Amended Summaries

Written by Customer Service on . Posted in Public Companies.

UAB “Orkela,” legal entity code 304099538, registered address at Jogailos St. 4, Vilnius, Republic of Lithuania (the Issuer), whose securities (the Bonds) are listed and admitted to trading on the Bond List of Nasdaq, also the Bonds are being publicly offered under the base prospectus approved by the Bank of Lithuania on 14 November 2023 (the Prospectus). On 24 November 2023 the Issuer through Nasdaq published a notice “Notice Regarding Approval of Supplement to Prospectus and Amended Summaries“. In order to clarify the information, the notice is updated as follows: The Issuer informs that the first supplement to the Prospectus has been approved by the Bank of Lithuania on 24 November 2023 (the Prospectus’ Supplement), that is attached.  Before deciding to invest in the Bonds, please carefully read the Prospectus’ Supplement....

Continue reading

Philips launches new-AI enabled innovations at #RSNA23 that free up healthcare providers to focus on patient care

Written by Customer Service on . Posted in Public Companies.

Healthcare professional viewing image on MR WorkspacePhilips Mobile MRI system expanding access to careA clinician using next generation EPIQ Elite VM10 with a patientNovember 26, 2023 New innovations help hospitals and health systems to consistently deliver accessible, high-quality care to patients in a sustainable way Amsterdam, the Netherlands and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today puts patients and healthcare providers center-stage at #RSNA23, the world’s largest medical imaging conference. Radiologists are looking for solutions to improve the performance of their departments and help patients with optimized workflows, shorter procedure times and user-friendly operations. With 45% of radiologists reporting symptoms of burnout, Philips’ innovations...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.